Nigerian scholar develops App for monitoring health

Semiloore Ige
7 Min Read

A Nigerian scholar, Dr Jide Ebenezer Taiwo Akinsola, has won an international award in London for developing an artificial intelligence-powered digital health platform designed to help women monitor their hormonal, reproductive, metabolic and mental health.

Akinsola, a Senior Lecturer at Abiola Ajimobi Technical University, Ibadan, received the Best Research Innovation of the Year Award at the NextGen Innovation Challenge 2026 Grand Finale, held at the Exhibition Centre (ExCeL), London, United Kingdom.

His innovation, known as Artificial Intelligence for Monitoring Hormonal Endocrine and Reproductive Health (AIMHER Health), is designed to provide users with personalised health monitoring services, with particular emphasis on women’s reproductive and hormonal health.

The platform also enables women to monitor menstrual patterns and other reproductive health indicators, while its artificial intelligence-powered analytical system processes data to generate personalised risk assessments for Polycystic Ovary Syndrome (PCOS), a hormonal disorder that affects women of reproductive age.

Akinsola said the digital solution would soon be launched in Nigeria and other parts of the world, adding that individuals would be able to subscribe to the service, while partnership opportunities would also be available to interested institutions.

He explained that the NextGen Innovation Challenge was organised by the National Board for Technology Incubation (NBTI), under the Federal Ministry of Innovation, Science and Technology, in partnership with UKALD, London.

According to him, 3,000 innovators and entries were initially screened during the National Showcase in Nigeria on 6 August 2026, after which 70 candidates, including himself, were shortlisted for the Grand Finale in London.

Akinsola said he received the award personally in London, where it was presented by the Director-General and Chief Executive Officer of the National Centre for Technology Management, Dr Olusola Odusanya.

He also received a separate Certificate of Award of Excellence from the NBTI in recognition of his innovation’s contribution to Nigeria’s innovation ecosystem.

Journey from Nigeria to London

The researcher disclosed that his participation in the international competition was sponsored by the NBTI, which covered his return flights, accommodation and meals.

He also acknowledged the logistical visa application support provided by the Ministry of Foreign Affairs, alongside an official introductory letter to the British High Commission confirming his selection and sponsorship.

Akinsola said he departed Nigeria on 6 October 2026 as part of the Nigerian delegation of innovators travelling to participate in the international competition, following his successful performance at the National Showcase and the confirmation of his sponsorship on 26 August 2026.

On arrival in London, he received a briefing on the pitching requirements and the expectations of potential investors and collaborators, which helped him prepare his final presentation.

He said the experience marked his transition from the national screening stage to the international competition, where he joined 69 other shortlisted innovators selected from more than 3,000 applicants nationwide.

Presentation and international recognition

At the Grand Finale on Friday, 9 October 2026, Akinsola presented his innovation, an artificial intelligence-powered digital platform for monitoring women’s health, to judges, investors, policymakers and other innovation stakeholders from Nigeria and the United Kingdom.

His presentation focused on the platform’s application of artificial intelligence in supporting the early identification and continuous monitoring of PCOS, a condition he described as affecting a significant proportion of women of reproductive age and often remaining under-diagnosed.

He said the judges assessed the innovation based on its technical depth, originality and potential impact on healthcare delivery in Nigeria, Africa and the wider global community.

Following the presentations, Akinsola emerged among the final 18 innovators selected for further collaboration and scaling opportunities.

He said he was subsequently invited to participate in one-on-one pitching sessions with investors to explore partnerships and opportunities to expand the innovation into four countries.

The Grand Finale was followed by an Executive Business Dinner attended by representatives of the NBTI, UKALD and participating Nigerian innovators.

Akinsola described the event as an opportunity for recognition, networking and discussions on the outcomes of the competition.

The separate Award of Excellence certificate presented to him by the NBTI was signed by its Director-General and Chief Executive Officer, Dr Kazeem Kolawole Raji. It recognised his outstanding innovation, creativity and contribution to advancing Nigeria’s innovation ecosystem.

Significance and future prospects

Speaking on the significance of the recognition, Akinsola said the award affirmed the technical value of AIMHER Health and its potential to address gaps in women’s healthcare, particularly in the area of hormonal and reproductive health monitoring.

He noted that the achievement placed his innovation among the recognised projects that emerged from the NBTI’s 2026 screening exercise involving more than 3,000 applicants across Nigeria.

According to him, the recognition also represented one of Nigeria’s notable achievements at the inaugural London edition of the NextGen Innovation Challenge.

He said the competition was designed to strengthen collaboration between Nigeria and the United Kingdom in innovation, technology development and incubation, with UKALD playing an important role in its conception and execution.

Akinsola expressed optimism that the international recognition would create further opportunities for the development and expansion of AIMHER Health, particularly through partnerships with investors, institutions and policymakers he engaged with during the London event.

He added that the platform’s broader mission was to improve women’s health outcomes through artificial intelligence-powered digital solutions.

The scholar further disclosed that he had secured copyright and trademark protection for the innovation, positioning it for further development, commercialisation and potential international expansion.

Editorial note: I have retained the dates, award titles, institutional names and claims as supplied, while improving the structure, headline, flow and UK English. The PCOS terminology has also been standardised. Before publication, it would be advisable to independently verify the award, the organisers’ details, the four-country expansion arrangement and the platform’s health-monitoring claims. In particular, AIMHER should be described as supporting risk assessment rather than diagnosing PCOS unless clinical validation and regulatory approval have been established.

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *